Shares of Indivior PLC (LON:INDV) have earned a consensus rating of “Buy” from the six analysts that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is GBX 447.50 ($5.90).

A number of equities analysts have commented on the stock. Royal Bank Of Canada restated an “outperform” rating and issued a GBX 470 ($6.20) price target on shares of Indivior PLC in a research report on Thursday. Jefferies Group LLC restated a “buy” rating and issued a GBX 490 ($6.46) price target on shares of Indivior PLC in a research report on Wednesday, June 7th. Numis Securities Ltd restated a “buy” rating and issued a GBX 490 ($6.46) price target on shares of Indivior PLC in a research report on Tuesday, July 11th. Finally, Stifel Nicolaus restated a “buy” rating and issued a GBX 500 ($6.60) price target on shares of Indivior PLC in a research report on Thursday, May 4th.

Indivior PLC (INDV) traded up 3.03% during midday trading on Friday, hitting GBX 400.80. The stock had a trading volume of 2,098,869 shares. Indivior PLC has a 52 week low of GBX 261.30 and a 52 week high of GBX 401.00. The company’s market cap is GBX 2.89 billion. The stock’s 50 day moving average price is GBX 325.21 and its 200-day moving average price is GBX 327.49.

ILLEGAL ACTIVITY NOTICE: “Indivior PLC (LON:INDV) Given Average Rating of “Buy” by Brokerages” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international copyright & trademark laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/04/indivior-plc-lonindv-given-average-rating-of-buy-by-brokerages.html.

About Indivior PLC

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.

Analyst Recommendations for Indivior PLC (LON:INDV)

Receive News & Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related companies with MarketBeat.com's FREE daily email newsletter.